文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

Presepsin指导缩短脓毒症患者抗生素疗程的潜在价值:一项多中心前瞻性队列试验

Potential Value of Presepsin Guidance in Shortening Antibiotic Therapy in Septic Patients: a Multicenter, Prospective Cohort Trial.
PubMed 文献 · Shock · 2022-01-01
一句话结论多中心前瞻性队列显示,presepsin指导的停药策略可显著增加28天内无抗生素天数,且不增加28天和90天死亡率、复发感染或多重耐药菌风险。

该多中心前瞻性队列试验纳入656例脓毒症患者,分配至presepsin指导组(n=327)或对照组(n=329)。presepsin组根据预设cut-off范围停用抗生素,对照组按国际指南停药。presepsin组28天内无抗生素天数显著多于对照组(14.54天 vs 11.01天,P<0.001),28天死亡率(17.7% vs 18.2%,P=0.868)和90天死亡率(19.9% vs 19.5%,P=0.891)无差异。presepsin组住院时间更短、住院费用更低,复发感染率和多重耐药菌率无差异。

要点

  • 在脓毒症患者中,presepsin指导组28天内无抗生素天数为14.54天(SD 9.01),显著多于对照组的11.01天(SD 7.73),P<0.001。
  • presepsin指导组28天死亡率为17.7%,对照组为18.2%(P=0.868);90天死亡率分别为19.9%和19.5%(P=0.891),均无显著差异。
  • presepsin指导组平均住院时间显著短于对照组,住院费用显著低于对照组。
  • 两组复发感染率、多重耐药菌率和SOFA评分趋势均无差异。
  • presepsin组抗生素停用依据为预设的presepsin浓度cut-off范围,具体阈值原文未提及。

适用人群与场景

  • 脓毒症患者,来自多中心前瞻性队列试验,初始708例中656例符合条件并纳入分析。
  • 排除人群原文未提及。

诊断标准与关键阈值

  • presepsin组根据预设的presepsin浓度cut-off范围停用抗生素,具体cut-off数值原文未提及。
  • 对照组根据国际指南停用抗生素。

处置流程与药物剂量

  • presepsin组:依据预设presepsin浓度cut-off范围决定停用抗生素,具体阈值、频次和疗程原文未提及。
  • 对照组:依据国际指南停用抗生素,具体方案原文未提及。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:多中心前瞻性队列试验;样本量656例(presepsin组327例,对照组329例);人群:脓毒症患者。
  • 主要终点:presepsin组28天内无抗生素天数14.54天(SD 9.01)vs 对照组11.01天(SD 7.73),P<0.001;28天死亡率17.7% vs 18.2%(P=0.868);90天死亡率19.9% vs 19.5%(P=0.891)。
  • 关键次要终点:presepsin组平均住院时间显著短于对照组,住院费用显著低于对照组;复发感染率、多重耐药菌率、SOFA评分趋势两组无差异。
  • 不良事件原文未提及。

证据类型、等级与局限

  • 证据类型:多中心前瞻性队列试验;证据等级或推荐强度原文未提及。
  • 局限:原文未明确提及;试验注册为回顾性注册(Retrospectively registered)。

对床旁实践的改变

  • 对于脓毒症患者,可考虑使用presepsin指导的停药策略以缩短抗生素疗程,但具体cut-off阈值原文未提及,需参考原始研究方案。
  • 该策略在不增加28天和90天死亡率、复发感染率和多重耐药菌率的前提下,可能缩短住院时间并降低住院费用。
  • 适用与不适用人群:原文仅提及脓毒症患者,排除人群原文未提及。
  • 常见陷阱:presepsin cut-off范围未在摘要中给出,不能直接套用;研究为前瞻性队列而非RCT,证据强度有限。

指南或共识出处

  • 原文未提及指南或共识名称;试验注册号ChiCTR1900024391。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

INTRODUCTION: Long-term use of antibiotics for septic patients leads to bacterial resistance, increased mortality, and hospital stay. In this study, we investigated an emerging biomarker presepsin-guided strategy, which can be used to evaluate the shortening of antibiotic treatment in patients with sepsis without risking a worse outcome.

METHODS: In this multicenter prospective cohort trial, patients were assigned to the presepsin or control groups. In the presepsin group, antibiotics were ceased based on predefined cut-off ranges of presepsin concentrations. The control group stopped antibiotics according to international guidelines. The primary endpoints were the number of days without antibiotics within 28 days and mortality at 28 and 90 days. Secondary endpoints were the percentage of patients with a recurrent infection, length of stay in ICU and hospital, hospitalization costs, days of first episode of antibiotic treatment, percentage of antibiotic administration and multidrug-resistant bacteria, and SOFA score.

RESULTS: Overall, 656 out of an initial 708 patients were eligible and assigned to the presepsin group (n = 327) or the control group (n = 329). Patients in the presepsin group had significantly more days without antibiotics than those in the control group (14.54 days [SD 9.01] vs. 11.01 days [SD 7.73]; P < 0.001). Mortality in the presepsin group showed no difference to that in the control group at days 28 (17.7% vs. 18.2%; P = 0.868) and 90 (19.9% vs. 19.5%; P = 0.891). Patients in the presepsin group had a significantly shorter mean length of stay in the hospital and lower hospitalization costs than control subjects. There were no differences in the rate of recurrent infection and multidrug-resistant bacteria and the SOFA score tendency between the two groups.

CONCLUSIONS: Presepsin guidance has potential to shorten the duration of antibiotic treatment in patients with sepsis without risking worse outcomes of death, recurrent infection, and aggravation of organ failure.

TRIAL REGISTRATION: ChiCTR, ChiCTR1900024391. Registered 9 July 2019-Retrospectively registered, http://www.chictr.org.cn.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Xiao H, Wang G, Wang Y, et al. Potential Value of Presepsin Guidance in Shortening Antibiotic Therapy in Septic Patients: a Multicenter, Prospective Cohort Trial. Shock. 2022. PMID: 34618727. doi:10.1097/SHK.0000000000001870

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。